NCT04194554View on ClinicalTrials.gov

A Multi-Center Trial of Androgen Suppression With Abiraterone Acetate, Leuprolide, PARP Inhibition and Stereotactic Body Radiotherapy in Prostate Cancer

PHASE1/PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

102

Participants

Timeline

Start Date

November 6, 2020

Primary Completion Date

November 30, 2026

Study Completion Date

May 31, 2027

Conditions
Prostate Cancer
Interventions
DRUG

Niraparib

given PO per dose escalation schedule

DRUG

Leuprolide

22.5 mg q3 month

DRUG

Abiraterone Acetate

1000 mg daily

RADIATION

Stereotactic body radiotherapy (SBRT)

5-6 fraction SBRT (total dose: 37.5-40 Gy)

Trial Locations (6)

10065

Cornell University, New York

Weill Cornell Medicine, New York

44106

University Hospitals Seidman Cancer Center, Cleveland

48109

University of Michigan Rogel Cancer Center, Ann Arbor

55901

Mayo Clinic, Rochester

75390

University of Texas Southwestern, Dallas

All Listed Sponsors
collaborator

Janssen Scientific Affairs, LLC

INDUSTRY

lead

University of Michigan Rogel Cancer Center

OTHER